AbCheck: Antibody Discovery Deal
(Thomson Reuters ONE) -
AbCheck s.r.o. /
AbCheck: Antibody Discovery Deal
Processed and transmitted by Thomson Reuters.
The issuer is solely responsible for the content of this announcement.
First validation of technology and business approach
Plzen, Czech Republic; October 05, 2010: AbCheck s.r.o., a Czech based company
specializing in the discovery and development of novel human high affinity
antibodies, announced today an antibody discovery deal with Eli Lilly and
Company, a global pharmaceutical company.
Under the agreement, AbCheck will use its three antibody discovery libraries to
deliver high-affinity, fully human antibodies against an undisclosed number of
Lilly targets. The three distinct human antibody libraries comprise a total of
about 10 billion sequentially and structurally diverse antibodies. Lilly, which
has full rights to any antibodies selected, will pay AbCheck discovery fees and
development milestone payments. Other financial and deal terms are not
disclosed.
"This discovery deal with Lilly is an important validation of our antibody
discovery and business approach," said Dr Volker Lang, Managing Director of
AbCheck. "Signing our first deal with such a significant company so soon after
setting up AbCheck, has certainly given us a tremendous boost of confidence that
AbCheck is following a successful business strategy."
AbCheck's libraries are designed as universal tools for the isolation of
antibodies against all possible targets. This breadth of targets differentiates
the libraries from immunized libraries, which are restricted to only a minor
fraction of therapeutically interesting target antigens.
For further information please contact:
AbCheck s.r.o. MC Services AG
Dr. Volker Lang (Managing Director) Birte Stein
Phone: +420 378 051500 Phone: +49 89 210 228 12
Fax: +420 378 051506 Fax: +49 89 210 228 88
E-Mail:V.Lang(at)abcheck.eu E-Mail:Birte.Stein(at)mc-services.eu
About AbCheck s.r.o.:
AbCheck, founded in 2009, specializes in customized antibody discovery and
screening for therapeutic applications. Based on three different fully human
antibody libraries, the technology portfolio covers all aspects regarding the
generation of therapeutic antibodies from research to lead optimization. The use
of three highly diversified libraries enables AbCheck to isolate very specific
human antibodies against virtually any target from a portfolio of more than 10
billion different antibodies. The company has isolated more than 25 different
therapeutic antibody drug candidates with characteristics such as high affinity
and high specificity for even the most difficult targets. AbCheck s.r.o. is a
spin-off of Affimed Therapeutics AG and is headquartered within the technology
park in Plzen, Czech Republic.
[HUG#1449136]
--- End of Message ---
AbCheck s.r.o.
null null null
Press release (PDF):
http://hugin.info/143842/R/1449136/391136.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: AbCheck s.r.o. via Thomson Reuters ONE
Datum: 05.10.2010 - 11:13 Uhr
Sprache: Deutsch
News-ID 44164
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 209 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"AbCheck: Antibody Discovery Deal"
steht unter der journalistisch-redaktionellen Verantwortung von
AbCheck s.r.o. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
